LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

4.41 -2.65

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.41

Max

4.78

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+65.2% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-52M 415M
Iepriekšējā atvēršanas cena	7.06
Iepriekšējā slēgšanas cena	4.41

Ziņu noskaņojums

By Acuity

45%

55%

137 / 344 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūn. 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

2026. g. 10. jūn. 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026. g. 10. jūn. 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026. g. 10. jūn. 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026. g. 10. jūn. 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

2026. g. 10. jūn. 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

2026. g. 10. jūn. 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026. g. 10. jūn. 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026. g. 10. jūn. 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026. g. 10. jūn. 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026. g. 10. jūn. 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026. g. 10. jūn. 23:38 UTC

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 10. jūn. 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026. g. 10. jūn. 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026. g. 10. jūn. 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

2026. g. 10. jūn. 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026. g. 10. jūn. 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Financial Services Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Basic Materials Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Health Care Roundup: Market Talk

2026. g. 10. jūn. 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026. g. 10. jūn. 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

65.2% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 65.2%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

137 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.